DOI: 10.1210/jcem-63-2-412
However, patients should continue to follow their prescribed treatments for sleep apnea, such as CPAP therapy, and consult their healthcare provider regularly to monitor progress
Unlike GLP-1 agonists, the changes are compositional rather than scale-weight driven: patients may not lose significant total body weight but will show meaningful reduction in waist circumference and visceral fat volume
This selectivity makes Ipamorelin one of the cleanest and most side-effect-free peptides available
This marks the first IPF therapy in 10 years to successfully achieve primary endpoints in Phase III clinical trials and gain approval, breaking a decade-long stagnation in the field and representing a major breakthrough in IPF treatment
Due to poor glycemic control, tirzepatide (a GIP/GLP-1RA) was started instead of sitagliptin (a dipeptidyl peptidase-4 inhibitor)